Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Seres Therapeutics Inc MCRB

Healthcare Biotechnology
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of... see more

Recent & Breaking News (NDAQ:MCRB)

Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates

Business Wire August 2, 2018

Seres Therapeutics to Host Second Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on August 2, 2018

Business Wire July 25, 2018

Report: Exploring Fundamental Drivers Behind Diamondback Energy, Global Net Lease, Ambac Financial Group, IDACORP, Francesca's, and Seres Therapeutics — New Horizons, Emerging Trends, and Upcoming Developments

GlobeNewswire June 19, 2018

Seres Therapeutics to Present at Two Upcoming June Conferences

Business Wire June 1, 2018

Seres Therapeutics to Host Microbiome R&D Event and Webcast on May 24, 2018

Business Wire May 17, 2018

Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates

Business Wire May 9, 2018

Seres Therapeutics to Host First Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on May 9, 2018

Business Wire May 7, 2018

Seres Therapeutics to Present at Two Upcoming May Conferences

Business Wire May 4, 2018

Seres Therapeutics Presents New Preclinical Data Supporting the Development of Microbiome Therapeutics for Immuno-Oncology at the 2018 American Association for Cancer Research Annual Meeting

Business Wire April 17, 2018

Seres Therapeutics to Present at Two Upcoming March Conferences

Business Wire March 9, 2018

Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates

Business Wire March 8, 2018

Seres Therapeutics Inc to Host Earnings Call

Accesswire March 8, 2018

Seres Therapeutics to Host Fourth Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on March 8, 2018

Business Wire March 2, 2018

Report: Developing Opportunities within AeroVironment, Seres Therapeutics, HFF, Fluor, KB Home, and H. B. Fuller — Future Expectations, Projections Moving into 2018

GlobeNewswire February 26, 2018

Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role of Chief Operating Officer

Business Wire January 31, 2018

Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide Mechanistic Support for Clinical Efficacy in Ulcerative Colitis

Business Wire January 4, 2018

Seres Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

Business Wire January 4, 2018

Seres Therapeutics Announces FDA Orphan Drug Designation for SER-287 in Treatment of Pediatric Ulcerative Colitis

Business Wire December 4, 2017

Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed™ Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team

PR Newswire November 14, 2017

Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for Cancer Immunotherapy Announce a Collaboration to Support the Investigation of Microbiome Therapeutics for Immuno-Oncology

Business Wire November 14, 2017